Diseñar la 'persona perfecta': el ambicioso plan de las grandes tecnológicas de Silicon Valley

TL;DR

Tech billionaires are investing in companies focused on genetic engineering and biotechnology.
The goal is to influence the biological composition of future generations, moving beyond standard medical treatments.
Companies like Genomic Prediction, Orchid, and Nucleus Genomics are developing tools for DNA analysis and risk prediction.
Orchid offers genetic testing of embryos for around 2,000 euros, providing risk scores for diseases.
The trend raises ethical concerns about technological eugenics and social inequality, with potential for standardizing traits.
Despite being in early stages, the investment and interest indicate an urgent discussion is needed.

Continuar leyendo el artículo original